These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8557970)

  • 21. Long-term prognosis in malignant or accelerated hypertension.
    Guerin C; Gonthier R; Berthoux FC
    Nephrol Dial Transplant; 1988; 3(1):33-7. PubMed ID: 3132637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left ventricular hypertrophy is a risk factor independent of hypertension in survival of hemodialyzed patients.
    Nakamura S; Sasaki O; Nakahama H; Inenaga T; Kimura G
    Ren Fail; 2002 Mar; 24(2):175-86. PubMed ID: 12071591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and pathological evaluation of hypertensive emergency-related nephropathy.
    Nonaka K; Ubara Y; Sumida K; Hiramatsu R; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Hoshino J; Sawa N; Takaichi K; Kuroda Y; Oohashi K
    Intern Med; 2013; 52(1):45-53. PubMed ID: 23291673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical presentation of malignant hypertension in Nigerians.
    Kadiri S; Olutade BO
    J Hum Hypertens; 1991 Aug; 5(4):339-43. PubMed ID: 1956031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microangiopathic hemolysis and renal failure in malignant hypertension.
    van den Born BJ; Honnebier UP; Koopmans RP; van Montfrans GA
    Hypertension; 2005 Feb; 45(2):246-51. PubMed ID: 15596574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs?
    Lip GY; Beevers M; Beevers DG
    Am J Hypertens; 2000 Aug; 13(8):934-9. PubMed ID: 10950403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excess smoking in malignant-phase hypertension.
    Isles C; Brown JJ; Cumming AM; Lever AF; McAreavey D; Robertson JI; Hawthorne VM; Stewart GM; Robertson JW; Wapshaw J
    Br Med J; 1979 Mar; 1(6163):579-81. PubMed ID: 427450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partial recovery of renal function in black patients with apparent end-stage renal failure due to primary malignant hypertension.
    James SH; Meyers AM; Milne FJ; Reinach SG
    Nephron; 1995; 71(1):29-34. PubMed ID: 8538845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Ponikowski P; Anker SD; Chua TP; Szelemej R; Piepoli M; Adamopoulos S; Webb-Peploe K; Harrington D; Banasiak W; Wrabec K; Coats AJ
    Am J Cardiol; 1997 Jun; 79(12):1645-50. PubMed ID: 9202356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing mortality in malignant hypertension.
    Isles CG; Lim KG; Boulton-Jones M; Cameron H; Lever AF; Murray G; Robertson JW
    J Hypertens Suppl; 1985 Dec; 3(3):S405-7. PubMed ID: 2856750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute renal failure associated with malignant hypertension].
    Gassanov N; Pollok M; Er F
    Dtsch Med Wochenschr; 2009 Oct; 134(44):2224-7. PubMed ID: 19847731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving survival of malignant hypertension patients over 40 years.
    Lane DA; Lip GY; Beevers DG
    Am J Hypertens; 2009 Nov; 22(11):1199-204. PubMed ID: 19696746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival after recovery from malignant nephrosclerosis.
    Nicholson GD
    Am J Hypertens; 1988 Jan; 1(1):73-5. PubMed ID: 3370137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].
    Kacso I; Gherman M; Mazouz H; Ghazali A; el Esper N; Morinière P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):19-28. PubMed ID: 10081033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of chronic haemodialysis after control of arterial hypertension; long term follow-up.
    Wauters JP; Brunner HR
    Proc Eur Dial Transplant Assoc; 1983; 19():182-7. PubMed ID: 6878232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
    Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
    Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Malignant arterial hypertension, symptomatic and prognostic aspects. Retrospective study of 140 cases].
    Guelpa G; Lucsko M; Chaignon M; Guedon J
    Schweiz Med Wochenschr; 1984 Dec; 114(50):1870-7. PubMed ID: 6515387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term renal survival in malignant hypertension.
    González R; Morales E; Segura J; Ruilope LM; Praga M
    Nephrol Dial Transplant; 2010 Oct; 25(10):3266-72. PubMed ID: 20299339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of electrocardiographic left ventricular hypertrophy in malignant hypertension and its correlation with renal function.
    Islim IF; Beevers M; Muthuswamy S; Bannergy A; Singh SP; Beevers DG
    J Hypertens Suppl; 1993 Dec; 11(5):S106-7. PubMed ID: 8158297
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.